About Elizabeth White

I am a highly experienced biopharmaceutical senior executive with a unique ability to bridge business strategy and scientific innovation and have made a smooth transition from large pharma to entrepreneurial biotech. I have a very broad skill set gained through leadership roles over a 35+ year career spanning new product planning, portfolio strategy, business development, R&D, operations, corporate communications, commercial planning, and global brand management. With a specialized understanding of genetic medicines and gene therapy, I am experienced in many therapeutic areas with strong expertise in rare diseases (particularly neurodegenerative, neuromuscular, hematologic, cardiovascular, pulmonary, and metabolic).

I am dedicated to helping emerging rare disease and genetic medicine biotechnology companies successfully and efficiently translate their innovative technologies into accessible medicines that will help patients in need. I am a passionate advocate for rare disease patients and served on the Board of Directors for Parent Project Muscular Dystrophy (PPMD) for a number of years. I am currently Co-Founder and Chief Operating Officer of the Orphan Therapeutics Accelerator, a unique non-profit biotech focused on ultra-rare disease drug development and access. I recently served as Chief Business Officer and Senior Vice President of Operations for Renovacor, a public preclinical cardiovascular gene therapy company, where I helped to lead the growth and development of the organization and portfolio and led the business development efforts resulting in Renovacor’s acquisition by Rocket Pharma. Prior to Renovacor, I was Chief Business and Strategy Officer for NeuExcell, a private preclinical gene therapy company focused on neurologic disorders, which was preceded by 20 years at Wyeth/Pfizer where I most recently led new product planning strategy as Assistant Vice President, Commercial Development, for Pfizer’s Rare Disease and Gene Therapy Business. I helped to build this business unit at Pfizer facilitating the completion of many successful licensing and acquisition deals, including the global collaboration and licensing deals with Spark Therapeutics and Sangamo Therapeutics and the acquisition of Bamboo Therapeutics.

I am proud to be involved in the development of the life science ecosystem in the Philadelphia Region. I am also an Entrepreneur-in-Residence at Yale Ventures, an Industry Advisor for Rutgers University, and on the Board of Visitors for Allegheny College.